CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
BörsenkürzelCRVO
Name des UnternehmensCervoMed Inc
IPO-datumNov 09, 2016
CEOAlam (John J)
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeNov 09
Addresse20 Park Plaza, Suite 424
StadtBOSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02116
Telefon16177444400
Websitehttps://cervomed.com/
BörsenkürzelCRVO
IPO-datumNov 09, 2016
CEOAlam (John J)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten